{"filings":[{"id":99853,"accession_number":"0000927653-26-000066","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q4 adj EPS $11.69 (+16% YoY); FY2027 guidance $43.80-$44.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $96.3B (+6%), full-year $403.4B (+12%); GAAP EPS $13.71, adjusted EPS $39.11 (+18% FY).","FY2027 adjusted EPS guidance $43.80-$44.60 (12-14% growth); reaffirms long-term 13-16% target.","Board approved $5.0B share repurchase increase (total $7.7B); $2.25B accelerated buyback entered.","Full-year cash from operations $6.2B, free cash flow $5.4B.","CEO cites specialty and biopharma services strength; Europe divestiture and Med-Surg separation progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":38.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":403430000000.0,"consensus_period":"2026-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99852,"accession_number":"0000927653-26-000053","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"McKesson enters $5B revolving credit facility maturing April 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $5.0B revolving credit facility replaces $1.0B 364-day and $4.0B five-year facilities.","Facility matures April 2031; includes $4.5B sublimit for CAD, GBP, EUR borrowings.","No borrowings outstanding at termination of prior facilities; total leverage covenant ≤4.25x (step-up to 4.75x for $500M+ acquisitions).","Interest rate based on ratings grid: SOFR loans 0.625% to 1.25% margin, base rate loans 0% to 0.25%.","Existing facilities terminated on April 24, 2026 upon effectiveness of new credit agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99851,"accession_number":"0000927653-26-000045","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"McKesson unit enters $2B senior secured credit facility with term loans and revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$750M term loan A-1 due 2031, $250M term loan A-2 due 2028, and $1B revolver due 2031.","Borrowings priced at SOFR + 1.25% or Base Rate + 0.25%; commitment fee 0.175%-0.225%.","Obligations secured by substantially all assets of borrower and certain U.S. subsidiaries.","Credit agreement includes customary covenants and quarterly financial maintenance tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116107,"accession_number":"0000927653-26-000038","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"McKesson reaffirms FY2026 outlook, sets Q4 earnings release for May 7, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 fiscal 2026 earnings to be released after market close on May 7, 2026; webcast at 4:30 PM ET.","CFO Britt Vitalone to present at Leerink Partners and Barclays conferences on March 11, 2026.","CFO also to participate in BofA Securities 2026 Healthcare Conference in May 2026.","Company reaffirms full year fiscal 2026 outlook as issued on February 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116106,"accession_number":"0000927653-26-000035","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"McKesson CFO Britt Vitalone to retire; Kenny Cheung named successor effective May 29, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Britt Vitalone retires as CFO effective May 28, 2026; will advise as contractor from July 2 at $50K/month.","Kenny Cheung appointed EVP & CFO effective May 29, 2026; previously CFO at Sysco Corporation.","Cheung receives $3.5M sign-on bonus, $6M sign-on RSUs, base salary $1.05M, 125% target bonus, plus equity.","Vitalone to advise on planned separation of McKesson's Medical Surgical Solutions (per press release).","Press release cites record Q3 revenue and adjusted operating profit as context for the transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116105,"accession_number":"0000927653-26-000015","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q3 revenue $106.2B +11%, adj EPS $9.34 +16%, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $9.59 vs $6.95 YoY; adjusted EPS $9.34 vs $8.03, up 16%.","Revenue of $106.2B, up 11% YoY; YTD revenue $307.1B, up 15%.","Raised FY 2026 adj EPS guidance to $38.80-$39.20 (prev. $38.35-$38.85).","Generated $1.2B operating cash flow and $1.1B free cash flow in Q3.","Closed sale of Norwegian retail/distribution businesses to NorgesGruppen on Jan 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":24.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":307135000000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132547,"accession_number":"0000927653-25-000138","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q2 adjusted EPS $9.86, +39% YoY; revenue record $103.2B; raises FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Quarterly revenue $103.2B (+10% YoY); GAAP EPS $8.92 vs $1.87; adjusted EPS $9.86 vs $7.07 (+39%).","Generated $2.2B free cash flow in Q2; cash from operations $2.4B.","Raised FY26 adjusted EPS guidance to $38.35-$38.85 (prev. $38.05-$38.55), indicating 16-18% growth.","CEO Brian Tyler cites strength in oncology/multispecialty and biopharma services as growth drivers.","Record first-half revenue of $201B (+16% YoY); net income $1.89B, up 64%."],"consensus_eps_estimate":null,"consensus_eps_actual":15.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":200977000000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149084,"accession_number":"0000927653-25-000125","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"McKesson raises FY2026 adj. EPS guidance to $38.05-$38.55; long-term growth target increased to 13%-16%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fiscal 2026 Adjusted EPS guidance raised and narrowed to $38.05-$38.55 from $37.10-$37.90.","Long-term Adjusted EPS growth target increased to 13%-16% from prior 12%-14%.","New segment long-term growth targets: North American Pharmaceutical 5%-8%, Oncology & Multispecialty 13%-16%, Prescription Technology Solutions 10%-13%.","Medical-Surgical separation and new organizational structure announced on Sept 18, 2025, reaffirmed at Investor Day.","Investor Day webcast on Sept 23, 2025; Q2 FY2026 earnings scheduled for Nov 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149083,"accession_number":"0000927653-25-000121","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"McKesson reorganizes into 4 segments; restates FY2025 revenue of $359B under new structure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Starting Q2 FY2026, McKesson will report 4 segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions.","FY2025 restated revenue: North American Pharm $304.5B, Oncology & Multispecialty $36.9B, Prescription Tech $5.2B, Medical-Surgical $11.4B; total $359.1B.","FY2025 restated adjusted op. profit: N.A. Pharm $3,145M (1.03%), Oncology & Multispecialty $936M (2.54%), Prescription Tech $961M (18.42%), Med-Surg $1,022M (8.98%).","Agreement to sell Norway operations signed Aug 4, 2025 (subject to regulatory approval); also intends to separate Medical-Surgical Solutions (announced May 2025).","Segment changes did not impact previously issued consolidated financials or EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149082,"accession_number":"0000927653-25-000105","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q1 FY26 revenue $97.8B (+23% YoY); Adj EPS $8.26, up 5%; raises FY26 guidance; dividend +15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $97.8B, up 23% YoY; GAAP diluted EPS $6.25 (down $0.75); Adjusted EPS $8.26 (up 5%).","FY2026 Adjusted EPS guidance raised to $37.10-$37.90 from $36.90-$37.70; indicates 12%-15% growth YoY.","Board approved 15% dividend increase to $0.82/share; 9th consecutive annual increase.","Closed acquisitions of controlling interests in PRISM Vision Holdings and Core Ventures during the quarter.","Net income attributable to McKesson $784M (down 14% YoY) due to prior-year gains."],"consensus_eps_estimate":null,"consensus_eps_actual":6.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":97827000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149081,"accession_number":"0000927653-25-000096","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"McKesson shareholders elect all 12 director nominees; ratify auditor; approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 board nominees elected; Maria N. Martinez received most votes against (6.1M of ~100M cast).","Deloitte & Touche LLP ratified as auditor for FY2026: 102.2M for, 8.6M against.","Advisory say-on-pay approved: 91.8M for, 8.0M against, 0.8M abstain.","Broker non-votes of 10.3M shares not counted on director and say-on-pay items.","Annual meeting held July 30, 2025; results filed August 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168066,"accession_number":"0000927653-25-000045","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"McKesson raises FY2026 adjusted EPS guidance to $36.90-$37.70 from $36.75-$37.55","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS guide increased by $0.15 at midpoint to $36.90-$37.70.","Effective tax rate reaffirmed at 17%-19%; H1 seen at 17%-20%, H2 at 16%-19%.","All other FY2026 guidance from May 8 earnings call reaffirmed.","Executives meeting investors today to discuss growth strategies and outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168065,"accession_number":"0001628280-25-028495","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["2.03","8.01","9.01"],"status":"ready","headline":"McKesson issues $2B notes to fund acquisition of 70% stake in Community Oncology Revitalization","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued $650M 4.650% notes due 2030, $650M 4.950% notes due 2032, $700M 5.250% notes due 2035.","Net proceeds ~$1.99B; combined with cash on hand to fund acquisition of 70% controlling interest in Community Oncology Revitalization Enterprise Ventures (Florida Cancer Specialists).","Interest payable semi-annually on May 30 and Nov 30, starting Nov 30, 2025.","Notes are unsecured, unsubordinated, rank equally with existing unsecured debt; change of control/rating downgrade triggers repurchase offer at 101% plus accrued interest.","Underwriters include Barclays, BofA Securities, Deutsche Bank, J.P. Morgan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168064,"accession_number":"0000927653-25-000034","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q4 revs $90.8B (+19%), adj. EPS $10.12 (+64%); guides FY26 adj. EPS $36.75-37.55; plans Med-Surg spin-off","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 consolidated revenues $90.8B (+19% YoY); GAAP diluted EPS $10.01; adjusted diluted EPS $10.12 (+64%).","Full-year FY25 revenues $359.1B (+16%); adjusted EPS $33.05 (+20%); cash flow from ops $6.1B, FCF $5.2B.","FY26 adjusted EPS guidance $36.75-$37.55 (11-14% growth); reaffirms long-term adj. EPS growth target 12-14%.","Announces intention to separate Medical-Surgical Solutions into independent company to unlock shareholder value.","U.S. Pharmaceutical long-term segment profit growth target raised from 5-7% to 6-8%."],"consensus_eps_estimate":9.3092,"consensus_eps_actual":25.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":359051000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185286,"accession_number":"0000927653-25-000010","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q3 FY2025 revenue $95.3B (+18% YoY), adj. EPS $8.03 (+4%); raises FY adj. EPS guidance to $32.55-$32.95","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $6.95 vs $4.42 prior year; adjusted EPS $8.03 vs $7.74 (+4%).","Consolidated revenue $95.3B (+18%); adjusted operating profit $1,463M (+16%).","Signed definitive agreement to acquire controlling interest in PRISM Vision Holdings (retina/ophthalmology).","Closed sale of Canada-based Rexall and Well.ca retail businesses on Dec 30, 2024.","FY2025 adjusted EPS guidance raised to $32.55-$32.95 from prior $32.40-$33.00 (19-20% growth vs FY2024)."],"consensus_eps_estimate":9.1295,"consensus_eps_actual":15.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":268228000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185285,"accession_number":"0000927653-25-000012","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K/A","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q3 FY25 revenue $95.3B (+18%); raises adjusted EPS guidance to $32.55-$32.95","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 FY25 revenue $95.3B (+18% YoY); GAAP EPS $6.95 (+57%); adjusted EPS $8.03 (+4%).","Raised and narrowed FY2025 adj. EPS guidance to $32.55-$32.95 from $32.40-$33.00, implying 19-20% growth.","Signed agreement to acquire controlling interest in PRISM Vision Holdings (retinal care) – deal size undisclosed.","Closed sale of Canada-based Rexall and Well.ca retail businesses on Dec 30, 2024.","Adjusted operating profit $1.463B (+16% YoY); net income attributable $879M (+49%)."],"consensus_eps_estimate":9.1295,"consensus_eps_actual":15.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":268228000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201867,"accession_number":"0000927653-24-000121","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q2 FY2025 revenue $93.7B (+21%), adj. EPS $7.07 (+13%), raises FY25 adj. EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $93.7B, +21% YoY; GAAP diluted EPS $1.87 (down 62% vs $4.92); adjusted EPS $7.07 (+13%).","Raises FY2025 adjusted EPS guidance to $32.40-$33.00 from $31.75-$32.55, implying 18-20% growth.","Announced agreement to acquire controlling interest in Florida Cancer Specialists & Research Institute's Core Ventures.","Announced agreement to sell Canada-based Rexall and Well.ca retail businesses."],"consensus_eps_estimate":8.228,"consensus_eps_actual":8.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":172934000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217909,"accession_number":"0000927653-24-000110","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["2.03","8.01","9.01"],"status":"ready","headline":"McKesson issues $500M 4.250% notes due 2029 to redeem higher-rate 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M aggregate principal of 4.250% Notes due 2029 at 99.946% of par.","Net proceeds ~$498M after underwriting discount; use to fund redemption of 5.250% Notes due 2026.","Notes rank equally with existing unsecured debt; redeemable at make-whole plus 15 bps before Aug 15, 2029.","Calls all $500M of 5.250% 2026 Notes at 100% plus accrued interest; refinancing lowers coupon by 100 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217908,"accession_number":"0000927653-24-000106","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"McKesson reaffirms FY2025 adj. EPS $31.75-$32.55, Q2 range $6.70-$7.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reaffirmed fiscal 2025 full-year adjusted EPS guidance $31.75-$32.55.","Projected Q2 fiscal 2025 adjusted EPS range $6.70-$7.00.","Presentation at Wells Fargo Healthcare Conference on Sept 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217907,"accession_number":"0000927653-24-000104","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"McKesson signs deal to buy 70% of Core Ventures (FCS) for ~$2.49B cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price approx. $2.49B in cash for ~70% controlling equity interest in Core Ventures (FCS's admin services org).","Florida Cancer Specialists (250+ physicians, 280+ APPs, ~100 FL locations) to join McKesson's The US Oncology Network.","Transaction subject to regulatory approvals and customary closing conditions; results reported in US Pharmaceutical segment.","McKesson CEO Brian Tyler states deal expands community oncology platform, improves patient outcomes and reduces cost of care.","FCS physicians retain minority interest in Core Ventures and remain independently owned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217906,"accession_number":"0000927653-24-000096","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q1 adjusted EPS $7.88 (+8% YoY); raises FY2025 guidance, boosts dividend 15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $79.3B (+6% YoY); net income $915M (-4%); GAAP EPS $7.00 flat.","Adjusted EPS $7.88 (+8% YoY); FY2025 adjusted EPS guidance raised to $31.75-$32.55.","Board approved 15% dividend increase to $0.71/share; 8th consecutive annual increase.","Share repurchase authorization increased by $4.0B to $9.9B total as of July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":7.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":79283000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217905,"accession_number":"0000927653-24-000084","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"McKesson shareholders elect all 11 directors, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 board nominees elected by majority; Brian S. Tyler received 103.4M for, 0.8M against.","Deloitte & Touche ratified as auditor for FY2025: 107.2M for, 7.4M against.","Advisory vote on executive compensation approved: 93.6M for, 10.1M against.","Charter amendment for officer exculpation approved: 87.9M for, 16.2M against.","Two shareholder proposals (independent chairman, reproductive health report) not approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237823,"accession_number":"0000927653-24-000044","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"McKesson elects Deborah Dunsire to board; two directors to step down at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah Dunsire, former CEO of H. Lundbeck, elected to McKesson board effective June 3, 2024; will serve on Compensation/Talent and Finance committees.","Linda Mantia (no longer independent) and Susan Salka (served nearly 10 years) will not stand for re-election at the 2024 annual meeting.","After the annual meeting, the board will be reduced to 11 members, 10 of whom are independent.","Dunsire brings over 30 years of experience in biopharmaceutical, oncology, and specialty industries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237822,"accession_number":"0000927653-24-000033","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson Q4 revenue +11% but adjusted EPS -14%; FY2025 guidance 14-17% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $76.4B (+11% YoY); full-year revenue $309B (+12% YoY).","Q4 adjusted EPS $6.18 (down 14% vs $7.19); full-year adjusted EPS $27.44 (+6% YoY).","Cash flow from operations $4.3B; free cash flow $3.6B for FY2024.","FY2025 adjusted EPS guidance $31.25–$32.05, implying 14%–17% growth.","Company provides no GAAP EPS forecast for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":22.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":308951000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255317,"accession_number":"0000927653-24-000018","cik":927653,"company_name":"MCKESSON CORP","ticker":"MCK","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"McKesson FQ3 revenue $80.9B (+15% YoY), adjusted EPS $7.74 (+12%), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $80.9B up 15% YoY; GAAP EPS from continuing ops $4.42 vs $7.65 (down 42%).","Adjusted EPS $7.74 vs $6.90; adjusted earnings $1,032M up 6%.","FY 2024 adjusted EPS guidance raised to $27.25-$27.65 from $26.80-$27.40.","US Oncology Network added Nashville Oncology Associates and SCRI Oncology Partners.","Year-to-date revenue $232.6B (+12%); adjusted EPS $21.24 (+13%)."],"consensus_eps_estimate":null,"consensus_eps_actual":16.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":232596000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90930765023.53049,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}